TABLE 3.
MICs for E. coli isolates
| E. coli isolate | MIC (μg/ml)a
|
||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amp | Pip | Pip/tazo | CTAZ | CTX | CFTI | CFOX | CPIM | Tet | T/S | Gent | Cipro | Strepc | Chlorc | Sulfc | |
| 9 | >16 | 32 | 16 | >16 | 32 | >8 | >32 | 1 | >8 | >1 | 1 | 0.03 | 6 | 6 | 6 |
| DH10B 9b | >16 | 64 | 16 | >16 | >32 | NTd | >32 | 1 | ≤4 | ≤0.5 | 0.5 | ≤0.015 | 6 | 6 | 28 |
| 164 | >16 | >128 | >64 | >16 | >32 | >8 | >32 | 2 | >8 | >1 | 8 | 0.03 | 6 | 6 | 6 |
| DH10B 164 | >16 | >128 | >64 | >16 | >32 | NT | >32 | 2 | >8 | >1 | 0.25 | ≤0.015 | 6 | 6 | 6 |
| 279 | >16 | >128 | 16 | 16 | 8 | 2 | >32 | 0.25 | >8 | >1 | >16 | >2 | 6 | 6 | 6 |
| DH10B 279 | >16 | >128 | 16 | >16 | 16 | NT | >32 | 0.5 | >8 | ≤0.5 | 16 | ≤0.015 | 6 | 6 | 6 |
| 292 | >16 | >128 | 16 | >16 | 32 | >8 | >32 | 0.5 | >8 | >1 | >16 | >2 | 6 | 6 | 6 |
| DH10B 292 | >16 | 128 | 16 | >16 | >32 | NT | >32 | 1 | >8 | ≤0.5 | >16 | ≤0.015 | 6 | 6 | 34 |
| 321 | >16 | >128 | 8 | >16 | 32 | 8 | >32 | 0.5 | >8 | >1 | 16 | ≤0.015 | 6 | 6 | 6 |
| DH10B 321 | >16 | >128 | 16 | >16 | >32 | NT | >32 | 1 | >8 | >1 | 16 | ≤0.015 | 6 | 14 | 6 |
| 665 | >16 | >128 | 16 | 16 | 16 | >8 | >32 | 1 | >8 | >1 | 8 | >2 | 6 | 6 | 6 |
| DH10B 665 | >16 | >128 | 32 | >16 | 32 | NT | >32 | 2 | >8 | >1 | 16 | ≤0.015 | 6 | 6 | 6 |
| 725 | >16 | >128 | 16 | >16 | 32 | >8 | >32 | 4 | >8 | >1 | 1 | >2 | 6 | 6 | 6 |
| DH10B 725 | >16 | >128 | 32 | >16 | >32 | NT | >32 | 4 | >8 | ≤0.5 | 1 | ≤0.015 | 6 | 6 | 6 |
| 771 | >16 | >128 | 8 | 8 | 16 | >8 | >32 | 1 | >8 | >1 | 8 | ≤0.015 | 6 | 6 | 6 |
| DH10B 771 | >16 | >128 | 16 | 16 | 32 | NT | >32 | 1 | >8 | ≤0.5 | 8 | ≤0.015 | 6 | 6 | 6 |
| Human 109 | >16 | >128 | 8 | >16 | 32 | >8 | >32 | 1 | >8 | >1 | >16 | >2 | 6 | 11.6 | 6 |
| DH10B H109 | >16 | >128 | 8 | >16 | 32 | NT | >32 | 0.25 | >8 | ≤0.5 | 0.5 | ≤0.015 | 6 | 6 | 6 |
| Human 826 | >16 | 128 | 8 | 16 | 8 | 8 | >32 | 0.5 | >8 | >1 | >16 | >2 | 6 | 6 | 6 |
| DH10B H826 | >16 | 128 | 8 | >16 | 16 | NT | >32 | 0.5 | >8 | >1 | 0.25 | ≤0.015 | 6 | 6 | 6 |
| DH10B | 4 | 4 | 2 | 0.5 | ≤0.25 | NT | 8 | ≤0.12 | ≤4 | ≤0.5 | 0.5 | ≤0.015 | 6 | 22 | 22 |
a
Amp, ampicillin; Pip, piperacillin; Pip/tazo, Piperacillin combined with a fixed concentration of tazobactam (4 μg/ml); CTAZ, ceftazidime; CTX, ceftriaxone; CFTI, ceftiofur; CFOX, cefoxitin; CPIM, cefepime; Tet, tetracycline; T/S, trimethoprim-sulfamethoxazole; Gent, gentamicin; Strep, streptomycin; Chlor, chloramphenicol; Sulf, sulfisoxazole; Cipro, ciprofloxacin.
b
E. coli DH10B transformants carrying the CMY-2 plasmid from the corresponding isolate.
c
Antimicrobial susceptibility determined by disk methodology.
d
NT, not tested.